JP2007511212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511212A5 JP2007511212A5 JP2006538818A JP2006538818A JP2007511212A5 JP 2007511212 A5 JP2007511212 A5 JP 2007511212A5 JP 2006538818 A JP2006538818 A JP 2006538818A JP 2006538818 A JP2006538818 A JP 2006538818A JP 2007511212 A5 JP2007511212 A5 JP 2007511212A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- protein
- promoter
- nucleic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 101
- 108090000623 proteins and genes Proteins 0.000 claims 68
- 102000004169 proteins and genes Human genes 0.000 claims 65
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 230000010076 replication Effects 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 101710199711 Early E1A protein Proteins 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 12
- 241000700605 Viruses Species 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000000824 cytostatic agent Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- 230000006037 cell lysis Effects 0.000 claims 3
- 230000001085 cytostatic effect Effects 0.000 claims 3
- 230000002074 deregulated effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000003362 replicative effect Effects 0.000 claims 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 241000700198 Cavia Species 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 108010082820 apicidin Proteins 0.000 claims 2
- 229930186608 apicidin Natural products 0.000 claims 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 2
- 229960003094 belinostat Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005616 epidermal appendage tumor Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
- 229950009213 rubitecan Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10353152 | 2003-11-14 | ||
| DE102004018117 | 2004-04-14 | ||
| PCT/EP2004/012931 WO2005052143A2 (de) | 2003-11-14 | 2004-11-15 | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Division JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511212A JP2007511212A (ja) | 2007-05-10 |
| JP2007511212A5 true JP2007511212A5 (https=) | 2008-01-10 |
Family
ID=34635104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538818A Pending JP2007511212A (ja) | 2003-11-14 | 2004-11-15 | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20060270016A1 (https=) |
| EP (1) | EP1689446B1 (https=) |
| JP (2) | JP2007511212A (https=) |
| CA (1) | CA2590257A1 (https=) |
| WO (1) | WO2005052143A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487811A1 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| JP5584393B2 (ja) | 2004-12-31 | 2014-09-03 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| CN101189003B (zh) | 2005-05-13 | 2012-02-08 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| JP5377968B2 (ja) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| EP1965824A4 (en) * | 2005-11-18 | 2011-10-19 | Gloucester Pharmaceuticals Inc | METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228 |
| WO2007145704A2 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| WO2008083288A2 (en) * | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals | Purifiction of romidepsin |
| EP2450049A1 (en) * | 2006-12-29 | 2012-05-09 | Gloucester Pharmaceuticals, Inc. | Romidepsin-based treatments for cancer |
| WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
| JP2010540426A (ja) * | 2007-09-25 | 2010-12-24 | トポターゲット ユーケー リミテッド | 特定のヒドロキサム酸化合物の合成方法 |
| AU2009220942B2 (en) * | 2008-03-07 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Methods of treatment employing prolonged continuous infusion of Belinostat |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| KR102020018B1 (ko) | 2009-03-02 | 2019-09-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 |
| SG10201505475XA (en) | 2010-07-12 | 2015-09-29 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| CA3092907A1 (en) * | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| SG11202012978VA (en) * | 2018-06-25 | 2021-01-28 | Ospedale San Raffaele Srl | Gene therapy |
| CN114269344A (zh) * | 2019-06-25 | 2022-04-01 | 微生物公司 | 用费洛西洛韦治疗或预防眼部感染的组合物和方法 |
| CN116179604B (zh) * | 2022-08-31 | 2025-08-26 | 上海锦斯生物技术有限公司 | 一种降低回复突变频率的重组5型腺病毒载体及其构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3816518B2 (ja) * | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| DE19929569A1 (de) * | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| US20030095989A1 (en) * | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| DE10150945A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| ES2287181T3 (es) * | 2000-12-28 | 2007-12-16 | Per Sonne Holm | Sistemas adenovirales y sus aplicaciones. |
| CA2487811A1 (en) * | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
| RU2393221C2 (ru) * | 2002-10-15 | 2010-06-27 | Пер Сонне ХОЛЬМ | Аденовирус с обращенной генной экспрессией и его применение |
-
2004
- 2004-11-15 EP EP04803146.2A patent/EP1689446B1/de not_active Expired - Lifetime
- 2004-11-15 US US10/579,543 patent/US20060270016A1/en not_active Abandoned
- 2004-11-15 CA CA002590257A patent/CA2590257A1/en not_active Abandoned
- 2004-11-15 WO PCT/EP2004/012931 patent/WO2005052143A2/de not_active Ceased
- 2004-11-15 JP JP2006538818A patent/JP2007511212A/ja active Pending
-
2010
- 2010-01-20 US US12/690,729 patent/US8586354B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 JP JP2011098213A patent/JP5618896B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511212A5 (https=) | ||
| Roth et al. | Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity | |
| JP6956159B2 (ja) | 腫瘍溶解性アデノウイルスによる脳癌の処置方法 | |
| Liang et al. | The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat | |
| Stuckey et al. | Stem cell-based therapies for cancer treatment: separating hope from hype | |
| Spitzweg et al. | The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment | |
| EA028590B1 (ru) | Ингибиторы мет для повышения эффективности лучевой терапии | |
| JP2017519039A5 (https=) | ||
| JP2008526188A5 (https=) | ||
| JP2007511507A (ja) | 癌を処置するための治療レジメン | |
| JP2008526189A5 (https=) | ||
| JP2005536447A (ja) | Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 | |
| JP2006512284A5 (https=) | ||
| Li et al. | Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine | |
| Goklany et al. | Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers | |
| JP2006518589A5 (https=) | ||
| ES2800162T3 (es) | Uso terapéutico de moduladores funcionales negativos de la eritropoyetina | |
| CA3028934C (en) | Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferation | |
| Cordier Kellerman et al. | Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma | |
| Hervé et al. | Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter | |
| JP6803619B2 (ja) | ＲＥＩＣ／Ｄｋｋ−３遺伝子およびチェックポイント阻害剤を用いた併用療法 | |
| WO2016066671A1 (en) | Method for treating resistant cancers using progastrin inhibitors | |
| WO2018064513A1 (en) | Natural killer cell-evasive oncolytic viruses | |
| Tsurushima et al. | Radiation-inducible caspase-8 gene therapy for malignant brain tumors | |
| Zhang et al. | Innovative DNA tetrahedron inspired by ancient mortise-and-tenon technique offers new immunotherapy strategy for metastatic breast cancer |